Shaanxi BLOOM Tech Co., Ltd. is one of the most experienced manufacturers and suppliers of hgh 176 191 peptide in China. Welcome to wholesale bulk high quality hgh 176 191 peptide for sale here from our factory. Good service and reasonable price are available.
HGH 176-191 Peptide is a specific active fragment derived from the C‑terminus of human growth hormone (HGH). Its most distinctive feature is its highly specific function and extremely low side effects. This peptide retains precisely the core fat‑reducing activity of HGH, while completely avoiding adverse reactions associated with full‑length HGH, such as blood glucose fluctuations, joint pain, and tissue edema.Meanwhile, this peptide has shown unique potential in anticancer research, including enhancing the toxicity of chemotherapeutic drugs and providing potential anticancer targets. It also has potential applications in muscle metabolism regulation, skin repair, and other fields, making it a novel peptide molecule with high specificity, safety, and multi‑domain potential.This peptide is usually supplied as a lyophilized powder and administered via injection on an empty stomach. It is currently widely used in fitness and fat‑reduction research, and also holds potential value in cartilage repair and metabolic regulation. It is the peptide of choice for precise fat reduction with minimal systemic burden.
Our products Form
hGH 176-191 COA
Core Applications and Mechanisms of it in Cartilage Repair
Cartilage tissue lacks blood vessels, nerves, and lymphatic supply, resulting in extremely poor self-repair capacity. Once injured, without timely intervention, it easily progresses to cartilage degeneration, osteoarthritis, and other diseases that severely impair joint function. Animal studies have confirmed that HGH 176-191 peptide regulates cartilage repair through multiple pathways and accelerates cartilage injury healing. Its core effects focus on two aspects: regulating growth factor secretion and promoting extracellular matrix synthesis. Meanwhile, it inhibits chondrocyte apoptosis, creating a stable microenvironment for cartilage repair and overcoming the difficulty of cartilage regeneration.
Regulating Growth Factor Secretion and Activating Cartilage Repair Pathways
Growth factors are key regulators in cartilage repair. Among them, insulin-like growth factor-1 (IGF-1) and transforming growth factor-β (TGF-β) critically promote chondrocyte proliferation, differentiation, and matrix synthesis.
Animal experiments show that it can specifically stimulate chondrocytes to secrete IGF-1. IGF-1 directly binds to receptors on the chondrocyte surface, activates intracellular signaling pathways, promotes chondrocyte proliferation, increases chondrocyte quantity, and provides sufficient cell sources for cartilage injury repair. Meanwhile, IGF-1 enhances the metabolic activity and synthetic function of chondrocytes, supporting the regeneration of cartilage matrix.
In addition, it regulates the expression of TGF-β, inhibits chondrocyte apoptosis and loss, and promotes the differentiation of chondrocytes into a mature phenotype, avoiding poor repair quality caused by abnormal chondrocyte proliferation.
In rat models of knee cartilage injury, intra-articular injection of it significantly increased the expression of IGF-1 and TGF-β in the injured area (p < 0.05), markedly reduced chondrocyte apoptosis, and greatly increased cell density compared with the control group. The repair process was shortened by more than 30%, fully verifying its role in accelerating cartilage repair by regulating growth factor secretion.
Promoting Extracellular Matrix Synthesis and Repairing Cartilage Defects
Extracellular matrix is the main component of cartilage tissue, primarily consisting of type II collagen and proteoglycans. Its content and structural integrity directly determine cartilage elasticity, toughness, and load-bearing capacity. After cartilage injury, extracellular matrix degradation occurs, making cartilage defects difficult to heal.
The product significantly promotes chondrocyte synthesis of type II collagen and proteoglycans, inhibits the activity of matrix metalloproteinases (MMPs), reduces extracellular matrix degradation, thereby filling the defect area and restoring the structural integrity of cartilage tissue.
In rabbit knee cartilage defect models, researchers injected it combined with hyaluronic acid into the injured site. After 4 weeks, histological sections showed obvious cartilage-like tissue regeneration in the injured area, with expression levels of type II collagen and proteoglycans close to normal cartilage, and significantly improved cartilage surface smoothness. After 8 weeks, the injured area was almost healed, and the elasticity and load-bearing capacity of cartilage gradually returned to normal. In contrast, the control group showed only a small amount of fibrous tissue hyperplasia without complete repair tissue.
These results demonstrate that HGH 176-191 peptide can effectively repair cartilage defects and improve repair quality by promoting extracellular matrix synthesis.
Application of it in Bone Health Maintenance
Besides cartilage repair, it also assists in maintaining bone health, mainly by improving osteoporosis and preventing bone degeneration. With its local action characteristics, it can target local bone repair needs and shows higher safety and specificity than full-length HGH in bone health applications.
Adjuvant Improvement of Osteoporosis and Enhancement of Bone Mineral Density
The core pathological features of osteoporosis are reduced bone mass, decreased bone mineral density, and destroyed bone microarchitecture, leading to high fracture risk. It is closely related to decreased osteoblast activity and increased osteoclast activity.
Animal studies found that it promotes osteoblast activity and proliferation, enhances the efficiency of bone matrix synthesis, inhibits osteoclast differentiation and activity, reduces bone resorption, thereby increasing bone mass and improving bone mineral density.
In ovariectomized rat osteoporosis models, continuous injection of it for 8 weeks significantly increased lumbar and femoral bone mineral density (p < 0.01), elevated bone mineral content, and effectively alleviated bone microarchitecture damage. The expression of alkaline phosphatase (ALP), an osteoblast activity marker, was significantly increased, while the expression of tartrate-resistant acid phosphatase (TRAP), an osteoclast activity marker, was notably decreased.
These results indicate that it can improve osteoporosis by regulating the balance between osteoblasts and osteoclasts, providing a new strategy for osteoporosis intervention, especially for populations who need to avoid the side effects of full-length HGH.
Unique Application Scenarios for Local Bone Repair
Unlike full-length HGH, it does not cause premature epiphyseal closure or excessive long bone growth. This advantage makes it particularly suitable for local bone repair, effectively compensating for the limitations of full-length HGH.
Full-length HGH acts widely on epiphyseal plates throughout the skeleton, accelerating epiphyseal closure, which may prematurely stop height growth in adolescents with open epiphyseal lines. In adults, excessive use may cause abnormal bone hyperplasia such as acromegaly. In contrast, it targets only the injured bone and cartilage tissue without regulating systemic skeletal growth, fundamentally avoiding these side effects.
Its main application scenarios include:
Local cartilage and bone repair for sports injuries, such as knee meniscus wear, ankle cartilage injury, and minor rib fractures in athletes. Local injection accelerates repair, shortens recovery time, and reduces the impact on athletic function.
Adjuvant repair after orthopedic surgery, such as joint replacement and cartilage transplantation. Local application promotes the survival of transplanted cartilage, accelerates bone–cartilage integration, improves surgical outcomes, and reduces complications such as joint stiffness and pain.
Local cartilage injury repair in adolescents with open epiphyseal lines. It achieves targeted repair without affecting systemic bone growth, ensuring normal development.
Application Advantages and Prospects of it in This Field
Compared with full-length HGH and other bone and cartilage repair-related substances, HGH 176-191 peptide has significant advantages in bone health and cartilage repair:
Strong targeting: it acts precisely on local bone and cartilage tissue, focusing on repair without affecting other systemic tissues, with extremely low side effects and high safety.
Clear repair efficacy: multiple animal studies confirm it effectively accelerates cartilage healing, improves bone mineral density, and restores normal physiological functions of bone and cartilage.
Manufacturability: as a synthetic peptide, it can be produced on a large scale via solid-phase synthesis, with high purity, good stability, and convenient storage and application.
Currently, applications of it in bone health and cartilage repair remain at the animal experimental stage and have not yet been fully translated clinically, but numerous studies have verified its great potential.
In the future, with advances in scientific research, clinical trials will be further conducted to optimize administration routes, clarify dosages, and explore combined applications with other repair materials (e.g., hyaluronic acid, stem cells), promoting its translation from research to clinical practice. In the near future, it is expected to become an important tool for bone health maintenance and cartilage injury repair, providing new therapeutic options for orthopedic patients, especially in sports injury rehabilitation, osteoporosis intervention, and adolescent cartilage injury treatment.
Foundational Research on Human Growth Hormone (HGH)
The discovery of HGH 176-191 peptide was built upon long-term exploration of human growth hormone. In the early 20th century, scientists first identified HGH in the human pituitary gland, but its extraction was extremely difficult and yield was scarce, restricting use to preliminary experimental research.
In 1963, Swiss scientist Fork Handle observed clinically that patients with pituitary removal exhibited abnormal metabolic indicators, which could be restored to normal levels after HGH supplementation. This initially revealed its physiological functions and laid the groundwork for subsequent fragment research.
In 1985, breakthroughs in genetic engineering enabled large‑scale production of HGH via recombinant DNA technology. In 1986, Eli Lilly and Company successfully synthesized a 191‑amino‑acid peptide chain identical to natural human HGH, making in‑depth research on HGH feasible.
Isolation and Preliminary Functional Study of HGH Fragments
From the 1980s to the 1990s, researchers focused on the structure‑function relationship of HGH and attempted to explore the biological activities of different regions through fragment isolation.
Starting in 1981, studies using protease hydrolysis to cleave the HGH molecule found that distinct fragments could retain specific physiological functions while avoiding the side effects of the full‑length molecule.
In 1990, Dr. Rodman published a paper in the New England Journal of Medicine proposing the theory that "human aging results from HGH deficiency", which greatly stimulated research interest in HGH fragments. Scientists began to selectively screen functionally specific fragments, including the terminal region of the HGH molecule.
Isolation and Identification of the product
In the mid‑1990s, research teams used solid‑phase peptide synthesis to precisely isolate the terminal 16‑amino‑acid fragment (positions 176 to 191) from the full‑length 191‑amino‑acid HGH molecule: HGH 176-191 peptide.
Studies showed that although this fragment accounts for only about 10% of the full‑length HGH molecule, it precisely retains lipolytic activity without the side effects of full‑length HGH, such as excessive bone growth and insulin resistance.
Characterized by spectroscopic and analytical techniques, its molecular formula is C₇₈H₁₂₃N₂₃O₂₂S₂ and molecular weight 1797 Da. The unique molecular structure and biological activity were formally established, marking the completion of discovery and characterization and opening the way for applied research.
Validation of Findings and Foundation for Applications
In the early discovery phase, animal studies further confirmed its functional advantages in regulating fat metabolism and preserving lean muscle mass, while also demonstrating potential value in cartilage repair and metabolic regulation.
With ongoing research, the findings on it were continuously refined. Its high targeting and strong safety were widely recognized, leading to gradual application in scientific model construction and novel drug development.
It has become an achievement of great research value in the peptide field, and also confirms the significance of early foundational HGH research and fragment screening.
FAQ
What is the difference between the product and CJC-1295?
+
-
It is a truncated sequence derived from the carboxyl-terminal region of growth hormone (hGH), while CJC-1295 is an analog of Growth Hormone-Releasing Hormone (GHRH), and Ipamorelin is a pentapeptide growth hormone secretagogue (GHS) that appears to mimic ghrelin-like activity.
What is the half life of it?
+
-
Like Growth Hormone, the product stimulates lipolysis (the breakdown or destruction of fat) and inhibits lipogenesis. It has a short half life with peak concentrations occurring around 15 minutes and not longer than 60 minutes after administration.
Hot Tags: hgh 176 191 peptide, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale, Bremelanotide Powder CAS 189691 06 3, Cosmetic, DERMORPHIN, dermorphin peptide, LONG R3 IGF I CAS 143045 27 6, Melanotan ii powder